To explore the role of 6PGD in tumor drug resistance and the potential for 6PGD as a clinical target, we used the S3 small molecule inhibitor of 6PGD, which can decrease 6PGD enzyme activity without affecting the expression level of 6PGD [16]. The gene discussed is PGD; the disease is neoplasm.